FDA Advises Against Antifungal Drug's Use In Studies

Law360, New York (October 16, 2013, 3:42 PM EDT) -- The U.S. Food and Drug Administration advised drugmakers on Wednesday not to use Johnson & Johnson's antifungal treatment Nizoral or similar oral medications in drug interaction studies, saying the risk of liver and kidney injury is too great.

The recommendation comes nearly three months after the FDA unveiled extensive warnings about the treatment, which is known generically as ketoconazole. The agency said in July that even short-term use of the medication's oral form can lead to serious liver and kidney damage.

Ketoconazole belongs to a class...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.